KK体育
EN
中文
EN
KK体育: About Us
About Us
Overview
History
Honor
Contact Us
Continuous innovation for better life
Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is an innovation-driven pharmaceutical company integrating the R&D, manufacturing, and sales of drugs. As a principal subsidiary of Hansoh Pharma (03692.HK), the Company is committed to improving human health through continuous innovation, particularly in the treatment of major diseases including the areas of oncology, infections, the central nervous system, metabolic disorders, and autoimmune disease.
KK体育:Innovation
Innovation
KK体育:Achievements
KK体育:Therapy Areas
R&D Platforms
KK体育:R&D Capability
Continuous innovation for better life
Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
Products
Products
Key Products
Continuous innovation for better life
After more than 20 years of continuous investment in R&D, Jiangsu Hansoh Pharma has marketed 7 innovative drugs and has over 30 innovative drug programs in different clinical stages with over 50 clinical trials in progress, forming a rich pipeline.
KK体育:Manufacturing
Manufacturing
Lean Manufacturing
KK体育:Quality Management
Continuous innovation for better life
Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and by using advanced production equipment.
Marketing Service
Marketing Service
KK体育:Market Coverage
KK体育:Hengte Pharmacy
Continuous innovation for better life
Under the new normal in the pharmaceutical industry, Jiangsu Hansoh Pharma endeavors to be proactive in the implementation of national policies and the innovation of business structure.
News
News
KK体育:Press Releases
KK体育:Media Center
Hansoh Pharma updates
Find the latest and most complete information about Hansoh Pharma!
Social Responsibility
Social Responsibility
Responsible Governance
KK体育:Green Development
KK体育:Public Charity
Responsibility integrity diligence innovation
Jiangsu Hansoh Pharma always adheres to the core values of responsibility, integrity, diligence, and innovation, serving human health with scientific and technological innovation, and assuming corporate social responsibility with accountable behavior in conducting business.
Careers
Careers
KK体育:Work with Us
Work with us
We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!
Search
中文
EN
About Us
Back
Overview
History
Honor
KK体育:Contact Us
Innovation
Back
Achievements
Therapy Areas
R&D Platforms
R&D Capability
Products
Back
Key Products
KK体育:Manufacturing
Back
KK体育:Lean Manufacturing
Quality Management
Marketing Service
Back
KK体育:Market Coverage
Hengte Pharmacy
News
Back
KK体育:Press Releases
Media Center
KK体育:Social Responsibility
Back
Responsible Governance
KK体育:Green Development
KK体育:Public Charity
Careers
Back
KK体育:Work with Us
Related Links
Media Center
Press Releases
KK体育:Media Center
Home
News
Media Center
Embarking on a New Era after a Century of Growth: Chinese Pharmaceutical Companies Transition from Generic to Innovative Medicines to Safeguard Public Health
Release Date：2021/06/29
Font Size
Source: Xinhua News Agency
Previous
Hansoh Pharma's Hengmu entered the list of "The 14th Healthy China Forum · Top 10 New Drugs"
Next
Ambrisentan Localized: China Approves First-to-market Ambrisentan Generic (Punuoan) of Hansoh Pharma
Back to list
Hot
2023/01/20
Several innovative drugs and new indications from Hansoh Pharma were included in the 2022 National Reimbursable Drug List
2023/01/18
Hansoh Pharma's CD19 mAb Xinyue opens a new era of reimbursable drugs for rare disease NMOSD
2022/12/05
Lyu Aifeng Outlines Strategies for Navigating the New Cycle at the 2022 China Healthcare Summit for Entrepreneurs, Scientists, and Investors
2022/12/02
Hansoh Pharma: EQRx's marketing authorization application for aumolertinib for the treatment of NSCLC with epidermal growth factor mutations was accepted by the EMA
2022/08/29
Innovative drugs contribute to one half of its revenue; in-house R&D and external BD collaboration both enter the fast lane - what's behind this pharmaceutical company's success?
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7fDzSfyJvbjbD",ck:"K9y7fDzSfyJvbjbD"});
k1体育(中国)官方网站app
k1体育·(中国)官方网站-手机APP下载
k1体育·(中国)平台官网
k1体育平台(中国)官网 - ios/安卓/手机版app下载
k1·体育(中国)官方网站-ios/安卓/手机版app下载
EN
